BR112022024179A2 - Tratamento de câncer - Google Patents

Tratamento de câncer

Info

Publication number
BR112022024179A2
BR112022024179A2 BR112022024179A BR112022024179A BR112022024179A2 BR 112022024179 A2 BR112022024179 A2 BR 112022024179A2 BR 112022024179 A BR112022024179 A BR 112022024179A BR 112022024179 A BR112022024179 A BR 112022024179A BR 112022024179 A2 BR112022024179 A2 BR 112022024179A2
Authority
BR
Brazil
Prior art keywords
cancer
breast cancer
cancer treatment
treatment
chemotherapy
Prior art date
Application number
BR112022024179A
Other languages
English (en)
Inventor
Triebel Frédéric
Original Assignee
Immutep Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008037.0A external-priority patent/GB202008037D0/en
Priority claimed from GBGB2018062.6A external-priority patent/GB202018062D0/en
Application filed by Immutep Sas filed Critical Immutep Sas
Publication of BR112022024179A2 publication Critical patent/BR112022024179A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

TRATAMENTO DE CÂNCER. Esta invenção se refere ao uso de uma proteína LAG-3 ou um derivado da mesma e, opcionalmente, um agente de quimioterapia para o tratamento de câncer em um indivíduo. O indivíduo pode ter uma ou mais de, uma baixa contagem de monócitos, um câncer de mama Luminal B, uma idade inferior a cerca de 85 anos, foi tratado anteriormente com um inibidor de CDK4/6 e não foi submetido anteriormente a tratamento com uma quimioterapia de taxano. Adequadamente, o câncer é um câncer de mama, como um câncer de mama positivo para receptor hormonal.
BR112022024179A 2020-05-28 2021-03-24 Tratamento de câncer BR112022024179A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2008037.0A GB202008037D0 (en) 2020-05-28 2020-05-28 Treatment of cancer
RU2020131384A RU2020131384A (ru) 2020-05-28 2020-09-23 Лечение рака
GBGB2018062.6A GB202018062D0 (en) 2020-11-17 2020-11-17 Treatment of cancer
PCT/EP2021/057588 WO2021239292A1 (en) 2020-05-28 2021-03-24 Treatment of cancer

Publications (1)

Publication Number Publication Date
BR112022024179A2 true BR112022024179A2 (pt) 2023-02-07

Family

ID=75362569

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024179A BR112022024179A2 (pt) 2020-05-28 2021-03-24 Tratamento de câncer

Country Status (11)

Country Link
US (1) US20230210946A1 (pt)
EP (1) EP4157313A1 (pt)
JP (1) JP2023527209A (pt)
KR (1) KR20230028321A (pt)
CN (1) CN116133674A (pt)
AU (1) AU2021280214A1 (pt)
BR (1) BR112022024179A2 (pt)
CA (1) CA3184309A1 (pt)
IL (1) IL298507A (pt)
MX (1) MX2022014909A (pt)
WO (1) WO2021239292A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152335A1 (en) * 2022-02-11 2023-08-17 Immutep S.A.S. Treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof

Also Published As

Publication number Publication date
EP4157313A1 (en) 2023-04-05
CN116133674A (zh) 2023-05-16
WO2021239292A1 (en) 2021-12-02
JP2023527209A (ja) 2023-06-27
CA3184309A1 (en) 2021-12-02
AU2021280214A1 (en) 2023-02-02
IL298507A (en) 2023-01-01
US20230210946A1 (en) 2023-07-06
KR20230028321A (ko) 2023-02-28
MX2022014909A (es) 2023-03-06

Similar Documents

Publication Publication Date Title
BR112018005777A2 (pt) anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produzir um anticorpo de interesse ou um fragmento do mesmo composição farmacêutica, e, uso de pelo menos um anticorpo
BR112017021688A2 (pt) composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
Larsen et al. Review of non-surgical treatment options for Peyronie's disease
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CY1124616T1 (el) Θεραπεια της μετα-βαριατρικης υπογλυκαιμιας με εξενδινη(9-39)
BR112022024179A2 (pt) Tratamento de câncer
NI201000091A (es) Inhibidores de cinesina como productos terapéuticos para el cáncer.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
MX2018009408A (es) Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos.
PE20091714A1 (es) Combinacion del inhibidor hgf y el agonista pten
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
BR112022011321A2 (pt) Compostos, polímeros, dispositivos e seus usos
ES2164899T3 (es) Uso de alcaloides de la clase lamellarina en metodos de tratamiento.
CL2022002239A1 (es) Tafoxiparina para el tratamiento de la preeclampsia
Heiduschka et al. The effect of resveratrol in combination with irradiation and chemotherapy
BR112017008805A2 (pt) tratamento de córnea usando laminina
BR112016030275A2 (pt) Métodos para tratamento e redução dos sintomas da síndrome mão-pé (eritrodisestesia palmo-plantar)
BR112018013804A2 (pt) entrega baseada em alimentos de agentes terapêuticos para tratamento de encefalopatia hepática
BR112021017829A2 (pt) Composto, e, composição farmacêutica para uso em prevenir ou tratar câncer
CL2022003507A1 (es) Composición y método para tratar el dolor crónico
ES1295226Y (es) Calcetin para el tratamiento del dolor en la tibia
BR112023019407A2 (pt) Composições farmacêuticas compreendendo zolmitriptano